Safety concerns raised for ArQule, Daiichi Sankyo's cancer drug
This article was originally published in Scrip
Executive Summary
US biotech company ArQule said a monitoring committee raised concerns about dosing level and the safety of a liver cancer therapy the drug maker is testing with partner Daiichi Sankyo.
You may also be interested in...
After Tivantinib Phase III Flop, ArQule Shifts Focus To Earlier-Stage Assets
ArQule devotes investor call about tivantinib failure in MET-high liver cancer to its other pipeline candidates, including the FGFR inhibitor ARQ 087, which will enter pivotal testing in intrahepatic cholangiocarcinoma, a rare type of liver cancer, this summer.
Baxter's Advate helps prevent bleeding in one-year study of hemophiliacs
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Bresch is looking to do a sizable deal
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.